Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: The immunomodulatory drugs thalidomide and lenalidomide recently received US Food and Drug Administration approval for the treatment of multiple myeloma.1-4 Venous thromboembolism (VTE) is a potentially serious complication associated with their use.5-8 We conducted a systematic review of thromboembolism occurring with immunomodulatory drug treatment of cancer.
Methods
We reviewed incidents of thalidomide- or lenalidomide-associated VTE among patients with cancer that were reported to the US Food and Drug Administration's MEDWATCH; reported in phase 2/3 clinical trials presented at hematology/oncology conferences in the United States, Europe, and Australia; or reported as articles published between 1998 and July 2006. Databases searched included PubMed and online abstracts for national and international hematology or oncology conferences. MeSH terms included thalidomide, lenalidomide, deep vein thrombosis, thromboembolism, and pulmonary embolism. The case definition of VTE included deep vein thromboembolism or pulmonary embolism diagnosed with vascular . . . [Full Text of this Article]
Charles L. Bennett, MD, PhD, MPP
cbenne@northwestern.edu
Cara Angelotta, BA
Division of Hematology/Oncology
Paul R. Yarnold, PhD
Department of Emergency Medicine
Andrew M. Evens, DO, MS
Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Ill
Jeffrey A. Zonder, MD
Division of Hematology-Oncology
Karmanos Cancer Institute
Wayne State University
Detroit, Mich
Dennis W. Raisch, PhD
VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center
University of New Mexico
Albuquerque
Paul Richardson, MD
Division of Hematologic Malignancy
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Mass
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-analysis
Nalluri et al.
JAMA 2008;300:2277-2285.
ABSTRACT
| FULL TEXT
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
Kristinsson et al.
Blood 2008;112:3582-3586.
ABSTRACT
| FULL TEXT
Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers
Bennett et al.
Arch Intern Med 2007;167:1041-1049.
ABSTRACT
| FULL TEXT
|
